LindaJeanBurnsMD
Oncology • Minneapolis, MNHematologic Oncology
Professor, Medicine, University of Minnesota Medical School
Are you Dr. Burns?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 85 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
University of Minnesota Physicians
516 Delaware Street SE PWB Fifth floor Clinic 5B
Minneapolis, MN 55455Phone+1 612-273-2800Fax+1 612-625-6919
Summary
- Dr. Linda Burns, MD is an oncologist in Minneapolis, Minnesota. She is currently licensed to practice medicine in Minnesota and Iowa. She is affiliated with M Health Fairview University of Minnesota Medical Center and is a Professor at University of Minnesota Medical School.
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1984 - 1988- University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1981 - 1984
University of Missouri-Columbia School of MedicineClass of 1981
Certifications & Licensure
MN State Medical License 1992 - 2025
IA State Medical License 1981 - 1994- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease Start of enrollment: 2000 Apr 01
- Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer Start of enrollment: 1999 May 01
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 21 citationsAdministrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.Jaime M. Preussler, Lih Wen Mau, Navneet S. Majhail, Christa Meyer, Ellen M. Denzen
Biology of Blood and Marrow Transplantation. 2016-10-01 - 257 citationsDiabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor studyK. Scott Baker, Kirsten K. Ness, Julia Steinberger, Andrea Carter, Liton Francisco
Blood. 2005-11-16 - 82 citationsPráticas recomendadas para triagem e prevenção de complicações em sobreviventes de longo prazo após transplante de células hematopoéticasNavneet S. Majhail, James Douglas Rizzo, Stephanie J. Lee, Mahmoud Aljurf, Yoshiko Atsuta
Revista Brasileira De Hematologia e Hemoterapia. 2012-01-01
Press Mentions
Leveling the Playing Field: Can We Achieve Gender Equality in Medicine?July 1st, 2018
Grant Support
- Mt2005-06-A Randomized Phase II Study Of Zolendronic Acid (ZOMETA) In The PrevenNational Center For Research Resources2007–2009
- 2008 Clinical Research Training Institute Summer WorkshopNational Heart, Lung, And Blood Institute2008
- Mt2005-14-Phase I OPEN Label, Single Arm, Dose Escalation Trial To Evaluate TheNational Center For Research Resources2008
- Mt2005-13-A Phase I OPEN Label, Single Arm, Dose Escalation Trial To Evaluate THNational Center For Research Resources2008
- Mt2005-14-A Phase I OPEN Label, Single Arm, Dose Escalation Trial To Evaluate THNational Center For Research Resources2007
- Mt2005-13-Phase I OPEN Label, Single Arm, Dose Escalation Trial To Evaluate TheNational Center For Research Resources2007
- Mt-2002-05-Post-Transplant Immunotherapy With Interleukin-2 (Il-2) And RituximabNational Center For Research Resources2007
- A Phase I OPEN Label, Single Arm, Dose Escalation Trial To Evaluate The BiodistrNational Center For Research Resources2006
- Post-Transplant Immunotherapy With Interleukin-2 (Il-2) And RituximabNational Center For Research Resources2004–2006
- A Phase I Study Of Ahn-12 In Patients With Advanced Leukemia/LymphomaNational Center For Research Resources2005
